Medifast, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel R. Chard
- Full Time Employees
- 504
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Address
- 100 International Drive Baltimore MD United States of America 21202
- IPO Date
- Dec 30, 1993
- CIK
- 0000910329
- Website
- medifastinc.com
- Similar Companies
- Business
- Medifast, Inc. Medifast, Inc. (NYSE: MED) operates as a health and wellness company that develops, manufactures, and sells clinically proven nutrition products and coach-guided lifestyle programs primarily through its OPTAVIA brand; core offerings include portion-controlled meal replacements such as bars, shakes, soups, puddings, oatmeal, pancakes, smoothies, and soft bakes, alongside the 5 & 1 Plan featuring Lean & Green meals, the Habits of Health Transformational System, and specialized lines like OPTAVIA ACTIVE for muscle health with Essential Amino Acid Blends and whey protein, and OPTAVIA ASCEND high-protein mini meals and nutrient packs tailored for GLP-1 medication users and weight maintenance. Products reach customers via a network of independent OPTAVIA Coaches using direct sales, e-commerce, and community support, targeting consumers seeking weight management, metabolic health, and lifelong healthy habits in the United States weight management market. Founded in 1980 and headquartered in Baltimore, Maryland, the company conducts operations mainly in the U.S. with over 40 years of experience, subsidiaries including Optavia (formerly Take Shape for Life), Jason Pharmaceuticals, and recent innovations backed by a Scientific Advisory Board. Recent developments encompass the 2024 launch of OPTAVIA ASCEND to address gaps in GLP-1 support and muscle preservation, an ongoing collaboration with LifeMD providing coach clients access to clinicians and GLP-1 medications including joint marketing pilots, a planned 2025 program with new OPTAVIA ASCEND products and a clinical study on integrated nutrition-lifestyle outcomes, and optimized marketing spend reductions to $20-25 million for 2024 while enhancing coach productivity amid revenue adjustments.
Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?
Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
Why Medifast's $15 Cash Per Share Makes It A Strong Buy
Medifast: Worth Putting On A Watchlist
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates
Medifast Announces First Quarter 2026 Financial Results
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)
Medifast's New Product Pipeline: Key Catalyst for Comeback?
Medifast (NYSE:MED) CEO Acquires $178,724.58 in Stock
Medifast Announces Cooperation Agreement with Steamboat Capital
Medifast (MED) Down 5.7% Since Last Earnings Report: Can It Rebound?
Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients